MLYS
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Mineralys Therapeutics, Inc. (MLYS) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D+). The rating has held at C for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.5) | C+ (2.6) | C (2.3) | D+ (1.7) | C+ (2.6) | C (2.3) |
| 2026-11-06 | C+ (2.5) | C+ (2.7) | C (2.3) | D+ (1.6) | C+ (2.7) | C (2.3) |
| 2026-10-30 | C+ (2.5) | C+ (2.6) | C (2.4) | C (2.3) | C+ (2.7) | C (2.5) |
| 2026-10-23 | C+ (2.5) | C+ (2.6) | C (2.3) | C- (2.1) | C+ (2.6) | C (2.4) |
| 2026-10-16 | C+ (2.5) | C+ (2.6) | C (2.3) | C- (2.1) | C+ (2.6) | C (2.4) |